2023-12-13 11:17:29
Present in all pharmacies, a list of 105 medications (88 of which are marketed in France) should be avoided according to a recent publication in the independent medical journal Prescribe. For 12 years, it has published a list of references to “discard for better treatment”. “Most often, when a drug treatment seems desirable, other options have a better risk-benefit balance than these drugs to be ruled out.”, is explained in the preamble to the 2024 report.
In this list, we find for example Smecta. The famous powder once morest intestinal disorders would present “natural lead pollution” according to the medical journal. Vogalène is also in the viewfinder and would expose “heart rhythm disturbances, ischemic strokes (at least with domperidone and metopimazine) and sudden deaths, adverse effects disproportionate to the symptoms treated and their low effectiveness on nausea and vomiting”.
In the cough medicine section, we find Toplexil or Muxol. The first cited “exposed to disproportionate adverse effects in the symptomatic treatment of cough”, for Muxol, the reference does not present “no demonstrated clinical effectiveness beyond that of a placebo”. Maxilase also falls into this placebo scenario and can expose to “sometimes serious skin or allergic disorders”.
“Minimal and transient effectiveness” for treatments once morest Alzheimer’s
Weight loss medications are incriminated and the journal Prescrire demonstrates “that no medication allows you to lose weight sustainably and without risk” and encourages people “to stick to physical activity and dietary modifications with, if necessary, psychological support”.
Treatments used for Alzheimer’s disease patients have “minimal and transient effectiveness. They are unwieldy due to disproportionate adverse effects and expose to numerous interactions. None of these drugs have demonstrated effectiveness in slowing the progression towards dependence and they are susceptible to serious, sometimes fatal, side effects.”. Several medications linked to multiple sclerosis are being singled out for a risk-benefit balance.clearly unfavorable”.
In its annual list, the journal recommends once morest a new pharmaceutical product: teriflunomide (Aubagio or other). It is an immunosuppressant now popular for treating multiple sclerosis. This drug was removed from the black list of the journal Prescrire last year.to assess its benefit-risk balance in children from the age of 10“. This balance is today considered “unfavorable”: he should therefore be “dismissed from care”.
Three drugs have, for their part, been removed from this black list. Fenfluramine (Fintepla and others), an amphetamine, was removed from the review because the medical journal evaluates its benefit-risk balance in a new authorized indication, Lennox-Gastaut syndrome in children. It remains to be ruled out as an addition to antiepileptic treatment in Dravet syndrome, a rare and serious form of childhood epilepsy.
Two drugs were also removed from the list because they are no longer marketed in France, Belgium or Switzerland: pholcodine, an opioid authorized for cough; and tixocortol oral spray, a corticosteroid authorized in combination with chlorhexidine for sore throats.
This investigation falls a month following the National Medicines Safety Agency (Ansm) sounded the alarm on vasoconstrictor (anti-cold) drugs.
1702469288
#Smecta #Voltarène #Maxilase #medical #journal #Prescrire #lists #drugs #dangerous
